Skip to the page

Data / Drug companies / Bora Pharmaceutical Services Inc.

Bora Pharmaceutical Services Inc.: 15 products in the FDA NDC directory, labeler code 53873

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Bora Pharmaceutical Services Inc. (labeler code 53873) lists 15 products in the FDA National Drug Code Directory. By type: 15 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on November 7, 2022.

The request: Watch Bora Pharmaceutical Services Inc. (FDA labeler code 53873): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
53873
Products in commercial distribution
15
Packages
21
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
0
Earliest marketing start
July 26, 2000
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Drugs for further processing15100%

Products by type

TypeProductsShare
Drugs for further processing15100%

Dosage forms

Dosage formProductsShare
Tablet, film coated746.7%
Capsule, extended release426.7%
Aerosol, metered213.3%
Gel16.7%
Capsule16.7%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Carvedilol phosphate53873-086Capsule, extended releaseDrugs for further processingNovember 7, 2022
Carvedilol phosphate53873-085Capsule, extended releaseDrugs for further processingNovember 7, 2022
Carvedilol phosphate53873-084Capsule, extended releaseDrugs for further processingNovember 7, 2022
Carvedilol phosphate53873-083Capsule, extended releaseDrugs for further processingNovember 7, 2022
Diclofenac sodium53873-080GelDrugs for further processingMay 19, 2021
Fluticasone propionate53873-078Aerosol, meteredDrugs for further processingFebruary 29, 2016
Fluticasone propionate53873-079Aerosol, meteredDrugs for further processingDecember 4, 2014
Zidovudine53873-070CapsuleDrugs for further processingOctober 28, 2010
Lamivudine53873-074Tablet, film coatedDrugs for further processingOctober 4, 2010
Lamivudine53873-073Tablet, film coatedDrugs for further processingOctober 4, 2010
Sumatriptan53873-059Tablet, film coatedDrugs for further processingDecember 19, 2003
Sumatriptan53873-058Tablet, film coatedDrugs for further processingDecember 17, 2003
Sumatriptan53873-057Tablet, film coatedDrugs for further processingDecember 17, 2003
Atovaquone and proguanil hydrochloride53873-072Tablet, film coatedDrugs for further processingJuly 26, 2000
Atovaquone and proguanil hydrochloride53873-071Tablet, film coatedDrugs for further processingJuly 26, 2000

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.